FDA support for FLUIDDA’s FRI technology in lung fibrosis

The US Food and Drug Administration has issued a letter of support for FLUIDDA’s Functional Respiratory Imaging (FRI) technology. The FDA encourages the use of FRI in clinical trials with patients suffering from Idiopathic Pulmonary Fibrosis (IPF).

Read more on BioPortfolio

Sorry, comments are closed for this post.